| 摘要 |
<p>The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R<SUB>4</SUB> group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R<SUB>4</SUB> group have improved aqueous solubility, stability in plasma and improved bioavailability.</p> |
| 申请人 |
WINSTON PHARMACEUTICALS, LLC;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS;GARST, MICHAEL, E.;SACHS, GEORGE;SHIN, JAI, MOO |
发明人 |
GARST, MICHAEL, E.;SACHS, GEORGE;SHIN, JAI, MOO |
